80.3 F
San Fernando
Wednesday, May 25, 2022

Calabasas Biotech Signs License Agreement

ArmaGen, a private biotech firm, has signed a licensing agreement to fund development of AGT-182, an investigational enzyme to treat degenerative nerve disorder Hunter syndrome. Under the agreement, Calabasas-based ArmaGen will receive payments up to $225 million, including an initial upfront payment of $15 million in cash and equity, from Shire plc, an Irish pharmaceutical company. In exchange, Shire will receive worldwide commercialization rights for AGT-182. The collaboration will be managed by a joint steering committee with representatives from both companies. AGT-182 is ArmaGen’s main investigational drug, and the company plans to start clinical trials before the end of the year. “Shire is the ideal partner for AGT-182, based on the company’s international reach and expertise in serving patients with Hunter syndrome,” James Callaway, chief executive of ArmaGen, said in a statement. Hunter syndrome is a rare, progressive and severe disorder in which the body can’t break down complex sugars. The buildup of these chemicals interferes with the functioning of certain organs, leading to serious complications including developmental delays and mental impairment.

Joel Russel
Joel Russel
Joel Russell joined the Los Angeles Business Journal in 2006 as a reporter. He transferred to sister publication San Fernando Valley Business Journal in 2012 as managing editor. Since he assumed the position of editor in 2015, the Business Journal has been recognized four times as the best small-circulation tabloid business publication in the country by the Alliance of Area Business Publishers. Previously, he worked as senior editor at Hispanic Business magazine and editor of Business Mexico.

Featured Articles

Related Articles